Introduction
============

Contralateral prophylactic/preventive mastectomy (CPM) patients with unilateral invasive breast cancer (BC) increased in the US by 150% since 1988, with no evidence of a geographic difference in practice or plateau effect.[@b1-bctt-7-001] The annual incidence of contralateral breast cancer (CBC) is 0.5% to 0.75%,[@b1-bctt-7-001] but has now radically decreased with the recent use of newer therapies such as Tamoxifen, aromatase inhibitors, Trastuzumab and neo/adjuvant chemotherapy.[@b2-bctt-7-001]--[@b5-bctt-7-001] Even in subgroups thought to be at higher risk for CBC, such as those younger than 45 years and those with lobular histologies, the actuarial CBC rate at 10 years remains \<7%.[@b2-bctt-7-001] At present, the only two groups of women at a substantially increased risk of CBC are those with *BRCA* mutations,[@b6-bctt-7-001] and women with a history of mantle irradiation during childhood and adolescence.[@b7-bctt-7-001]

A Cochrane Review published by Lostumbo et al[@b8-bctt-7-001] found that although CPM reduces the risk of developing CBC, there is insufficient evidence that CPM improves survival. Although it is unclear why the aggressive and irreversible procedure of CPM is growing in prevalence, speculation includes that greater awareness and availability of genetic testing may be responsible, but this is uncertain.[@b1-bctt-7-001],[@b9-bctt-7-001],[@b10-bctt-7-001] In a recent study on 2,504 patients using multivariate logistic regression to identify independent predictors of CPM, 30.6% of patients \<50 years of age underwent CPM compared with only 18.2% of women ≥50 years of age (odds ratio \[OR\] =2.2). They were more likely to be surgeon identified, White race (OR =3.3), have a family history of BC (OR =2.9), have invasive lobular histology, be able to have immediate reconstruction (OR =3.3), and have multicentric disease. Most of these women did not have positive genetic mutation findings.[@b9-bctt-7-001] Another study suggested increased rates of CPM were associated with having a female surgeon.[@b11-bctt-7-001],[@b12-bctt-7-001]

However, these previous studies were not performed using large comprehensive databases. Therefore, the current study explored factors associated with use of CPM in a large enriched population-based cancer registry database which included demographic, clinical and co-morbidity factors. The main aim of this study was to determine which demographic and social factors were associated with receipt of CPM. As previous research has shown that disparities in treatments and procedures in the care of BC patients (eg, time to initiation of chemotherapy[@b13-bctt-7-001] or adjuvant radiation, and use of breast conserving surgery)[@b14-bctt-7-001]--[@b16-bctt-7-001] are associated with race, ethnicity, socioeconomic status (SES) and insurance status,[@b17-bctt-7-001]--[@b19-bctt-7-001] we were particularly interested in exploring the association of these variables with receipt of CPM. Our secondary aim was to investigate clinical (treatment and hospital characteristics) and comorbidity associations with CPM surgery.

Materials and methods
=====================

Our study used data from three sources to investigate CPM in patients with invasive BC. The Florida Cancer Data System (FCDS), a population-based Florida cancer registry, was used to identify BC patients diagnosed from 1996 to 2009. Florida's Agency for Health Care Administration (AHCA) database provided procedure and diagnoses information from all in- and out-patient facilities, and data from the US census provided a proxy for individual SES. Female patients who were 18 years or older were included if they resided in Florida during the study period. Patients with carcinoma in situ or with missing data on surgery (bilateral or unilateral), race, ethnicity, SES, marital status or insurance status were excluded from the study. Patients with unilateral BC were identified by having a single record of malignant neoplasm of the breast with diagnostic code 174 (2012 version of International Classification of Diseases, Ninth Revision (ICD-9)). Patients with more than one 174 code either with the same date or different dates were assumed to be multifocal, bilateral, or recurrent BC, and were excluded from the study. As the majority of patients receive surgical treatment at the time of diagnosis, patients receiving CPM later in the course of their disease were not included in this study.

The dichotomous primary outcome variable was whether the patient had CPM (yes/no). Patients' sociodemographic variables were age at diagnosis, race (White, Black, other), ethnicity (Hispanic and non-Hispanic), neighborhood SES based on percent of individuals living below the federal poverty line from US census tract-level information (lowest SES ≥20%, middle-low ≥10% and \<20%, middle-high \[≥5% and \<10%\], or highest \<5%), marital status (never married, married, or divorced/separated/widowed), primary payer at diagnosis (private insurance, Medicare, Medicaid, defense/military, Indian Health Service, other insurance, or uninsured), urban or rural geographic residence (by zip code), and characteristics of the treating facility (teaching vs non-teaching hospital and high vs low volume hospital). Clinical characteristics included tumor and treatment related variables such as the Surveillance, Epidemiology, and End Results (SEER) stage, histological differentiation grade, and history of chemotherapy or radiation. Finally, comorbidities were available for all patients based on ICD-9 diagnoses.

Statistical analysis
--------------------

Demographic and clinical characteristics of patients were calculated as frequencies and percentages for categorical variables and means and standard deviations (Std) for continuous variables, and compared for all patients in the population, and then for patients with unilateral and CPM. To assess what demographics and clinical factors were significantly associated with having a CPM, multivariate logistic regression models using generalized estimation equations were fitted. Robust standard errors were calculated to take into account clustering of patients within facilities. The first multivariate model (Model 1) included covariates for sociodemographic and clinical variables; the second multivariate model (Model 2) included all diagnostic information to fully adjust for other co-morbidities. Adjusted ORs, corresponding 95% confidence intervals (95% CIs), and *P*-values were calculated from these models. Statistical significance was considered at *P*\<0.05. All statistical analyses were performed using SAS v 9.3 for Windows (SAS Institute Inc., Cary, NC, USA). The study was approved by the Institutional Review Boards of both University of Miami and Florida Department of Health.

Results
=======

Between 1996 and 2009, 54,275 women were diagnosed with invasive BC and underwent a unilateral or CPM. Of these, 32,667 records had no data on whether there was unilateral or bilateral disease, race, ethnicity, SES, marital status, or insurance status, and therefore these cases were excluded from the analyses, for a final sample of 21,608 patients with unilateral disease and a record of the type of surgery. Descriptive statistics for demographics characteristics are provided for overall sample and by laterality of procedure done ([Table 1](#t1-bctt-7-001){ref-type="table"}). Mean age at diagnosis of all patients was 67.5 years (Std =13.9). The majority of patients were White (19,684; 91.1%), while 1,625 (7.5%) were Black, and 299 (1.4%) were other races. Non-Hispanics (19,257; 89.1%) outnumbered the Hispanics (2,351; 10.9%). There were 719 (3.3%) uninsured patients, 642 (3%) on Medicaid compared to 6,342 (29.4%) with private insurance and 11,778 (54.5%) on Medicare.

Of the 21,608 patients in our population, all with a single unilaterally diagnosed lesion, 837 (3.9%) underwent bilateral mastectomy. Those who had CPM were significantly younger (mean =56.9 years, SD =14.2) than those who had a unilateral procedure (mean =68 years, SD =13.7). Only 2.8% of Black patients had CPM as compared to 3.9% of White patients (*P*\<0.001). Lower rates of CPM were seen in non-Hispanic patients (3.8%) compared to Hispanics (4.5%). There was a monotonic relationship between SES and rate of CPM, with CPM increasing from 2.9% in the lowest SES up to 5.3% in the highest SES (*P*\<0.001).

Clinical characteristics of all patients and patients with unilateral and CPM are shown in [Table 2](#t2-bctt-7-001){ref-type="table"}. Patients undergoing CPM have lower rates of four or more comorbid conditions than those undergoing unilateral procedures (40.6% vs 58.1%) and are more likely to get adjuvant chemotherapy (23.7% vs 11.7%), but are similar on other clinical and pathological characteristics.

In the multivariate logistic regression model without co-morbidities ([Table 3](#t3-bctt-7-001){ref-type="table"}; Model 1), Black patients were less likely than Whites to have CPM (OR =0.55, 95% CI =0.39--0.78, *P*\<0.001). Those in the highest SES category were more likely to have CPM compared with lowest SES category (OR =1.37, 95% CI =1.06--1.76, *P*=0.016). Uninsured patients had significantly lower rates of CPM as compared with privately insured patients (OR =0.58, 95% CI =0.36--0.95, *P*=0.029). As patients aged they were less likely to undergo this surgery (OR =0.95, 95% CI =0.94--0.96, *P*\<0.001). The characteristics of the facility where patients were treated also played a significant role, as patients at non-teaching compared to teaching (OR =0.69, 95% CI =0.49--0.99, *P*=0.042) and low compared to high volume hospitals (OR =0.53, 95% CI =0.39--0.72, *P*\<0.001) had significantly lower rates of CPM. Finally, those patients with an SEER graded tumor stage of regional, lymph nodes only, had almost a 25% lower rate of CPM as compared to patients with localized disease (OR =0.78, 95% CI =0.62--0.98, *P*=0.03).

When co-morbidities were included in the multivariate analysis ([Table 3](#t3-bctt-7-001){ref-type="table"}; Model 2), the only results that changed in a substantative way, ie, went from significant to non-significant, were that patients at non-teaching hospitals no longer had significantly lower CPM rates (*P*=0.091) and patients with a SEER stage of regional, lymph nodes only, no longer had lower rates than those with localized disease, indicating that once comorbidities were controlled for, patients with a worse tumor stage were no longer more likely to receive CPM. We also were able to investigate whether any comorbidities were associated with receipt of CPM. We found that two comorbidities were associated with a higher likelihood of CPM: fluid and electrolyte disorder (OR =1.23, 95% CI =1.01--1.49, *P*=0.038) and depression (OR =1.52, 95% CI =1.24--1.85, *P*\<0.001); and two were associated with a lower rate of CPM: deficiency anemia (OR =0.64, 95% CI =0.43--0.95, *P*=0.028) and neurological disorders (OR =0.66, 95% CI =0.45--0.99, *P*=0.44) (results not shown in table). Throughout the period of data collection, the rates of CPM are about 2% from 1996 to 2000 but increase up to 8% in 2008 ([Table 4](#t4-bctt-7-001){ref-type="table"}).

Discussion
==========

In this study using large, comprehensive databases, we found a number of associations between demographics characteristics and the likelihood of undergoing CPM. For example, we found that Black women were significantly less likely than Whites to undergo CPM. This may be due to physician differential advice on risks and benefits of this procedure or system issues such as access. Previous studies of clinicians' prescription and treatment behavior have revealed racial differences in the treatment of breast carcinoma, as well as other conditions for Black patients, including neoadjuvant therapy for esophageal and gastric cancer, chronic cardiac conditions, and lower extremity amputation for peripheral vascular disease.[@b17-bctt-7-001],[@b18-bctt-7-001],[@b20-bctt-7-001]--[@b35-bctt-7-001]

We found that age, SES, and insurance status were associated with which patients were more likely to receive a CPM. For SES in the fully adjusted model, we found that patients living in highest SES neighborhoods had a 38% greater likelihood of undergoing CPM compared with the lowest SES. Whether this is a reflection of education of that group or access to health care cannot be concluded from analyses of our large dataset. Older patients were less likely to undergo CPM, but it is unclear if this is related to higher anxiety in younger women, different self-image in older women, or some other factor. Finally, uninsured patients in our study were less likely to have CPM compared with those patients who are privately insured; whether this is related to access to care or patient preference is unclear.

Hospital characteristics were also found to be significant predictors of CPM in our study. In the model adjusted for all covariates other than comorbidities, those treated in non-teaching hospitals were less likely to have CPM than those in teaching hospitals. This became non-significant when co-morbidities were added to the model. However, those in low vs high volume hospitals remained less likely to undergo CPM in the fully adjusted model controlling for comorbidities. This could be an admission rate bias or a lower threshold in high volume centers where more complex procedures are embarked upon more frequently.

A novel finding for us was that a few comorbidities were associated with a statistically significant incidence of CPM; the strongest association was with major depression where patients with depression were over 50% more likely to undergo CPM (OR =1.52; 95% CI =1.24--1.85, *P*\<0.001). The limited research that has been done on the psychosocial implications of the preventive surgery suggests that prophylactic mastectomy may be effective in reducing distress levels in high-risk women.[@b36-bctt-7-001]--[@b39-bctt-7-001] Therefore, it may be that a higher likelihood of undergoing CPM is associated with a larger fear of CBC and higher levels of distress and depression after a diagnosis of unilateral breast cancer. Conversely, those with deficiency anemia (OR =0.64, 95% CI =0.43--0.95, *P*=0.028) or neurological disorders (OR =0.66, 95% CI =0.45--0.99, *P*=0.44), were approximately 35% less likely to undergo CPM; this may stem from a clinical recognition of these patients being less suitable for the more extensive surgery.

Limitations of this study include a relatively small sample size for appropriate subgroup analysis and the lack of data about the presence of BRCA deleterious mutations. Also, the FCDS and AHCA databases do not contain accurate or sufficient information on hormone receptor-negative status of tumors, and therefore, we were unable to explore the association of estrogen/progesterone receptors or triple negative patients with receipt of CPM. Finally, detailed information on additional risk factors such as number and degree of affected relatives or opportunities for nonsurgical risk reduction are not available in the databases. Nonetheless, this study is based on a large statewide cancer registry database and allows us to examine a wide variety of associations of demographic, clinical and comorbid characteristics, with choice of CPM. Thus, it paves the way for subsequent studies that will look more in depth into factors affecting whether patients undergo CPM, in order to ensure treatment equality for all patients.

In conclusion, CPM rates reveal significant differences among patients of different race, socioeconomic class, and insurance coverage. The reasons for these differences as well as the rising rates of CPM in the face of lack of evidence of survival benefits remain unexplained. It seems that personal and psychosocial factors are driving the choices about this treatment. It may be that more public health education is needed to better inform patients in their decision making process. Health care delivery systems optimization for more equitable and accessible delivery of breast cancer care, at the same standard, to different socioeconomic classes of patients, at different geographical locations, and regardless of insurance status, should be planned and attempted. More in-depth study of the causes of these disparities is critically needed so as to guide future planning for health care delivery in this area.
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###### 

Sociodemographic characteristics of female breast cancer patients from the Florida Cancer Data System and Agency for Health Care Administration datasets (1996--2009)

                                All female patients   Laterality of procedure done                                          
  ----------------------------- --------------------- ------------------------------ -------- ------- ------- ----- ------- -----
  All                           21,608                100.0                          20,771   100.0   96.1    837   100.0   3.9
  Race                                                                                                                      
   White                        19,684                91.1                           18,919   91.1    96.1    765   91.4    3.9
   Black                        1,625                 7.5                            1,579    7.6     97.2    46    5.5     2.8
   Other                        299                   1.4                            273      1.3     91.3    26    3.1     8.7
  Hispanic origin                                                                                                           
   Non-Hispanic                 19,257                89.1                           18,526   89.2    96.2    731   87.3    3.8
   Hispanic                     2,351                 10.9                           2,245    10.8    95.5    106   12.7    4.5
  Race and ethnicity                                                                                                        
   White/Non-Hispanic           17,408                80.6                           16,747   80.6    96.2    661   79.0    3.8
   White/Hispanic               2,276                 10.5                           2,172    10.5    95.4    104   12.4    4.6
   Black/Non-Hispanic           1,577                 7.3                            1,531    7.4     97.1    46    5.5     2.9
   Black/Hispanic               48                    0.2                            48       0.2     100.0                 
   Other/Non-Hispanic           272                   1.3                            248      1.2     91.2    24    2.9     8.8
   Other/Hispanic               27                    0.1                            25       0.1     92.6    2     0.2     7.4
  SES                                                                                                                       
   Lowest                       2,628                 12.2                           2,553    12.3    97.1    75    9.0     2.9
   Middle-low                   6,597                 30.5                           6,376    30.7    96.6    221   26.4    3.4
   Middle-high                  7,926                 36.7                           7,623    36.7    96.2    303   36.2    3.8
   Highest                      4,457                 20.6                           4,219    20.3    94.7    238   28.4    5.3
  Marital status                                                                                                            
   Never married                2,227                 10.3                           2,129    10.2    95.6    98    11.7    4.4
   Married                      11,240                52.0                           10,700   51.5    95.2    540   64.5    4.8
   Divorced/separated/widowed   8,141                 37.7                           7,942    38.2    97.6    199   23.8    2.4
  Primary payer at diagnosis                                                                                                
   Uninsured                    719                   3.3                            690      3.3     96.0    29    3.5     4.0
   Private insurance            6,342                 29.4                           5,906    28.4    93.1    436   52.1    6.9
   Medicaid                     642                   3.0                            613      3.0     95.5    29    3.5     4.5
   Medicare                     11,778                54.5                           11,538   55.5    98.0    240   28.7    2.0
   Defense/military/veteran     206                   1.0                            196      0.9     95.1    10    1.2     4.9
   Indian health services       41                    0.2                            39       0.2     95.1    2     0.2     4.9
   Insurance, NOS               1,880                 8.7                            1,789    8.6     95.2    91    10.9    4.8
  Tobacco use                                                                                                               
   Never                        11,148                51.6                           10,719   51.6    96.2    429   51.3    3.8
   History                      3,876                 17.9                           3,707    17.8    95.6    169   20.2    4.4
   Current                      2,341                 10.8                           2,246    10.8    95.9    95    11.4    4.1
   Unknown                      4,243                 19.6                           4,099    19.7    96.6    144   17.2    3.4
  Urban/rural living                                                                                                        
   Rural                        1,383                 6.4                            1,351    6.5     97.7    32    3.8     2.3
   Urban                        20,225                93.6                           19,420   93.5    96.0    805   96.2    4.0
  Teaching hospital                                                                                                         
   No                           19,470                90.1                           18,792   90.5    96.5    678   81.0    3.5
   Yes                          2,138                 9.9                            1,979    9.5     92.6    159   19.0    7.4
  Hospital volume                                                                                                           
   Low                          13,474                62.4                           13,125   63.2    97.4    349   41.7    2.6
   High                         8,134                 37.6                           7,646    36.8    94.0    488   58.3    6.0

**Notes:** SES, neighborhood SES was based on percent of individuals living below the federal poverty line from US census tract-level information: lowest (≥20%), middle-low (≥10% and \<20%), middle-high (≥5% and \<10%), or highest (\<5%).

**Abbreviations:** SES, socioeconomic status; NOS, not otherwise specified.

###### 

Clinical and pathological characteristics of female breast cancer patients in Florida (1996--2009)

                                                      All female patients   Laterality of procedure done                                         
  --------------------------------------------------- --------------------- ------------------------------ -------- ------- ------ ----- ------- ------
  All                                                 21,608                100.0                          20,771   100.0   96.1   837   100.0   3.9
  Elixhauser co-morbidity count                                                                                                                  
   None                                               454                   2.1                            417      2.0     91.9   37    4.4     8.1
   1--2                                               3,719                 17.2                           3,479    16.7    93.5   240   28.7    6.5
   3--4                                               5,027                 23.3                           4,807    23.1    95.6   220   26.3    4.4
   \>4                                                12,408                57.4                           12,068   58.1    97.3   340   40.6    2.7
  Surveillance, Epidemiology, and End Results stage                                                                                              
   Unknown/unstaged                                   1,072                 5.0                            1,036    5.0     96.6   36    4.3     3.4
   Localized                                          15,380                71.2                           14,750   71.0    95.9   630   75.3    4.1
   Regional, direct extension ± lymph nodes           1,068                 4.9                            1,039    5.0     97.3   29    3.5     2.7
   Regional, lymph nodes only                         3,675                 17.0                           3,544    17.1    96.4   131   15.7    3.6
   Distant                                            413                   1.9                            402      1.9     97.3   11    1.3     2.7
  Histological grade                                                                                                                             
   Unknown/not stated                                 3,849                 17.8                           3,710    17.9    96.4   139   16.6    3.6
   Well-differentiated                                3,836                 17.8                           3,677    17.7    95.9   159   19.0    4.1
   Moderately differentiated                          8,121                 37.6                           7,805    37.6    96.1   316   37.8    3.9
   Poorly differentiated                              5,507                 25.5                           5,294    25.5    96.1   213   25.4    3.9
   Undifferentiated                                   295                   1.4                            285      1.4     96.6   10    1.2     3.4
  Histological type                                                                                                                              
   Ductal carcinoma                                   15,836                73.3                           15,223   73.3    96.1   613   73.2    3.9
   Lobular carcinoma                                  3,612                 16.7                           3,443    16.6    95.3   169   20.2    4.7
   Other                                              2,160                 10.0                           2,105    10.1    97.5   55    6.6     2.5
  Adjuvant chemotherapy                                                                                                                          
   Unknown                                            1,002                 4.6                            969      4.7     96.7   33    3.9     3.3
   No                                                 17,988                83.2                           17,382   83.7    96.6   606   72.4    3.4
   Yes                                                2,618                 12.1                           2,420    11.7    92.4   198   23.7    7.6
  Adjuvant radiation therapy                                                                                                                     
   Unknown                                            621                   2.9                            605      2.9     97.4   16    1.9     2.6
   No                                                 16,670                77.1                           15,912   76.6    95.5   758   90.6    4.5
   Yes                                                4,317                 20.0                           4,254    20.5    98.5   63    7.5     1.5
  Death within 30 days of surgery                                                                                                                
   No                                                 21,482                99.4                           20,647   99.4    96.1   835   99.8    3.9
   Yes                                                126                   0.6                            124      0.6     98.4   2     0.2     1.6
  Survival status                                                                                                                                
   Dead                                               4,871                 22.5                           4,803    23.1    98.6   68    8.1     1.4
   Alive                                              16,737                77.5                           15,968   76.9    95.4   769   91.9    4.6.

###### 

Multivariate logistic regression models for the primary binary outcome of undergoing bilateral mastectomy from the FCDS and AHCA datasets (1996--2009)

  Variable                                            Category            Model 1             Model 2[\*](#tfn3-bctt-7-001){ref-type="table-fn"}                       
  --------------------------------------------------- ------------------- ------------------- ---------------------------------------------------- ------------------- ---------
  Race                                                White               1.00 (reference)                                                         1.00 (ref)          
  Black                                               0.55 (0.39, 0.78)   \<0.001             0.59 (0.42, 0.83)                                    0.002               
  Other                                               1.27 (0.83, 1.93)   0.270               1.31 (0.87, 1.99)                                    0.200               
  Hispanic                                            Non-Hispanic        1.00 (ref)                                                               1.00 (ref)          
  Hispanic                                            1 (0.78, 1.27)      0.972               0.99 (0.79, 1.25)                                    0.965               
  SES                                                 Lowest              1.00 (ref)                                                               1.00 (ref)          
  Middle-low                                          1.08 (0.83, 1.41)   0.551               1.09 (0.83, 1.41)                                    0.545               
  Middle-high                                         1.15 (0.85, 1.56)   0.352               1.16 (0.86, 1.58)                                    0.329               
  Highest                                             1.37 (1.06, 1.76)   0.016               1.38 (1.07, 1.8)                                     0.014               
  Age at diagnosis                                    Years               0.95 (0.94, 0.96)   \<0.001                                              0.95 (0.94, 0.96)   \<0.001
  Marital status                                      Never married       1.00 (ref)                                                               1.00 (ref)          
  Married                                             1.07 (0.84, 1.37)   0.573               1.08 (0.85, 1.38)                                    0.519               
  Divorced/separated/widowed                          0.99 (0.76, 1.27)   0.908               0.99 (0.76, 1.28)                                    0.931               
  Primary payer at diagnosis                          Private insurance   1.00 (ref)                                                               1.00 (ref)          
  Uninsured                                           0.58 (0.36, 0.95)   0.029               0.60 (0.36, 0.98)                                    0.043               
  Medicaid                                            0.83 (0.59, 1.17)   0.292               0.81 (0.57, 1.15)                                    0.230               
  Medicare                                            0.86 (0.67, 1.11)   0.248               0.86 (0.67, 1.11)                                    0.249               
  Defense/military/veteran                            0.81 (0.46, 1.45)   0.482               0.80 (0.45, 1.42)                                    0.440               
  Indian/public                                       0.72 (0.24, 2.11)   0.547               0.66 (0.22, 1.97)                                    0.461               
  Insurance, NOS                                      0.70 (0.55, 0.89)   0.004               0.7 (0.55, 0.89)                                     0.003               
  Urban/rural living                                  Urban               1.00 (ref)                                                               1.00 (ref)          
  Rural                                               0.83 (0.55, 1.25)   0.371               0.82 (0.54, 1.25)                                    0.355               
  Teaching hospital                                   Teaching hospital   1.00 (ref)                                                               1.00 (ref)          
  Non-teaching hospital                               0.69 (0.49, 0.99)   0.042               0.73 (0.51, 1.05)                                    0.091               
  Hospital volume                                     High                1.00 (ref)                                                               1.00 (ref)          
  Low                                                 0.53 (0.39, 0.72)   \<0.001             0.53 (0.4, 0.72)                                     \<.001              
  Surveillance, Epidemiology, and End Results stage   Localized           1.00 (ref)                                                               1.00 (ref)          
  Regional, direct extension ± lymph nodes            0.93 (0.67, 1.28)   0.651               0.99 (0.7, 1.4)                                      0.969               
  Regional, lymph nodes only                          0.78 (0.62, 0.98)   0.030               0.85 (0.64, 1.14)                                    0.276               
  Distant                                             0.83 (0.45, 1.55)   0.568               0.94 (0.46, 1.91)                                    0.862               

**Notes:**

Model 2 also includes comorbidities. OR (95% CI): Odds ratio and 95% confidence interval. SES = neighborhood SES was based on percent of individuals living below the federal poverty line from US census tract-level information: lowest (≥20%), middle-low (≥10% and \<20%), middle-high (≥5% and \<10%), or highest (\<5%).

**Abbreviations:** FCDS, Florida Cancer Data System; AHCA, Florida's Agency for Health Care Administration; SES, socioeconomic status; NOS, not otherwise specified.

###### 

Rates of CPM (1996--2009)

                      No       Yes                   
  ------------------- -------- -------- ------ ----- -----
  **CPM**                                            
  All                 21,608   20,771   96.1   837   3.9
  Year of diagnosis                                  
   1996               1,640    1,604    97.8   36    2.2
   1997               1,054    1,032    97.9   22    2.1
   1998               1,069    1,046    97.8   23    2.2
   1999               1,314    1,287    97.9   27    2.1
   2000               1,221    1,200    98.3   21    1.7
   2001               1,210    1,181    97.6   29    2.4
   2002               1,301    1,267    97.4   34    2.6
   2003               1,478    1,437    97.2   41    2.8
   2004               1,482    1,431    96.6   51    3.4
   2005               1,972    1,907    96.7   65    3.3
   2006               1,920    1,828    95.2   92    4.8
   2007               1,902    1,801    94.7   101   5.3
   2008               2,011    1,879    93.4   132   6.6
   2009               2,034    1,871    92.0   163   8.0

**Abbreviation:** CPM, contralateral prophylactic mastectomy.

[^1]: \*These authors contributed equally to this work
